STOCK TITAN

Alkermes plc. (ALKS) SEC Filings, Feb 20-25, 2026

ALKS NASDAQ

Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.

Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.

Rhea-AI Summary

Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported equity compensation activity involving restricted stock units and ordinary shares. On 2/23/2026, 6,407 restricted stock units were exercised into 6,407 ordinary shares at a price of $0.00 per share, reflecting a derivative exercise or conversion. To cover tax obligations, 2,845 ordinary shares were disposed of at $32.19 per share through a tax-withholding transaction. After these movements, Nichols directly owned 112,762 ordinary shares. Each restricted stock unit represents a right to receive one ordinary share, and units vest in four equal annual installments beginning 2/23/2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.00%
Tags
insider
-
Rhea-AI Summary

Alkermes plc EVP and COO Jackson Blair Curtis reported equity transactions on 2/23/2026. He exercised a restricted stock unit award, converting 8,738 restricted stock units into 8,738 ordinary shares at a stated price of $0.0000 per share.

To cover tax obligations related to this equity compensation, 3,880 ordinary shares were disposed of in a tax-withholding transaction at $32.1900 per share. After these transactions, Curtis directly owned 236,681 ordinary shares. Each restricted stock unit represents one ordinary share and vests in four equal annual installments beginning on 2/23/2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.00%
Tags
insider
-
Form 4
Rhea-AI Summary

Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised 7,689 restricted stock units into ordinary shares on February 23, 2026, with each unit converting into one share. On the same date, 3,414 ordinary shares at $32.19 per share were withheld to cover tax obligations, leaving him with 89,572 ordinary shares held directly. The restricted stock unit award vests in four equal annual installments beginning on February 23, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.00%
Tags
insider
Rhea-AI Summary

Alkermes plc executive David Joseph Gaffin, EVP and CLO of Alkermes, Inc., reported the vesting and exercise of 7,689 restricted stock units into ordinary shares on February 23, 2026. In a related tax-withholding disposition, 3,414 ordinary shares were used at $32.19 per share. Following these transactions, he directly holds 235,877 ordinary shares. The restricted stock unit award vests in four equal annual installments beginning February 23, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.00%
Tags
insider
-
Rhea-AI Summary

Alkermes plc describes a global neuroscience-focused biopharmaceutical business built around proprietary drugs for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, plus licensed and technology-partnered products.

The company completed the acquisition of Avadel Pharmaceuticals in February 2026, adding LUMRYZ, the first once-at-bedtime sodium oxybate for narcolepsy, and a dedicated commercial organization. Alkermes highlights key products ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL, royalty-generating collaborations with Janssen and Biogen, and a late-stage pipeline led by alixorexton, an orexin 2 receptor agonist with FDA Breakthrough Therapy designation in narcolepsy. The filing also outlines extensive patent protection, manufacturing arrangements, intense competitive pressures and numerous business risks, including reliance on a few major products, regulatory and IP challenges, debt obligations and potential volatility in its ordinary shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
annual report
-
Rhea-AI Summary

Alkermes plc announced a planned CEO transition. Long‑time Chief Executive Officer Richard F. Pops will retire from the CEO role effective July 31, 2026, after about 35 years, and will remain non‑executive Chairman while serving as Senior Advisor through December 31, 2026.

Executive Vice President and Chief Operating Officer Blair C. Jackson has been appointed to become CEO effective August 1, 2026. Jackson has more than two decades at Alkermes in scientific, operational and strategic roles and previously served as interim principal financial officer.

Under a letter agreement, Pops will receive a $75,000 monthly cash retainer as Senior Advisor, a fiscal 2026 cash bonus at target level prorated for his CEO service, and a 2026 time‑based restricted stock unit award with a grant value of $2,687,500, prorated to reflect service through the Senior Advisor term and scheduled to vest on December 31, 2026. He will also receive a prorated $40,000 annual retainer for his service as non‑executive Chairman, continued vesting of existing equity awards under specified post‑service terms, and reimbursement of up to $60,000 in legal fees related to the transition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
current report
Rhea-AI Summary

Alkermes plc reported 2025 total revenue of $1.48 billion, down from $1.56 billion, as royalties declined after the INVEGA SUSTENNA® U.S. royalty expiry, even though proprietary net sales rose to $1.18 billion. LYBALVI® grew to $346.7 million, ARISTADA® to $370.0 million and VIVITROL® to $467.9 million.

GAAP net income for 2025 was $241.7 million, or $1.43 diluted EPS, compared with $367.1 million and $2.17 in 2024, and Adjusted EBITDA declined to $394.0 million. The company closed its Avadel acquisition, using about $775 million of cash and adding $1.525 billion of term loans, gaining LUMRYZ® and a stronger sleep-medicine franchise. For 2026, Alkermes expects revenues of $1.73–$1.84 billion, proprietary net sales driven by VIVITROL®, LYBALVI®, ARISTADA® and LUMRYZ®, but a GAAP net loss of $(115)–$(135) million and Adjusted EBITDA of $370–$410 million as it absorbs Avadel-related costs and ramps its orexin portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
current report
-
Rhea-AI Summary

Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity award transactions involving restricted stock units (RSUs) and ordinary shares. On February 18 and 19, 2026, RSU awards were exercised, converting 2,034 and 2,991 RSUs into the same number of ordinary shares at a price of $0.00 per share.

To cover tax obligations, Parisi disposed of 706 ordinary shares at $32.02 and 979 ordinary shares at $32.00 through share withholding transactions coded "F," which are described as payments of tax liability by delivering securities. After these transactions, he directly held 11,057 ordinary shares. Footnotes state that each RSU represents a right to one ordinary share, that one award is fully vested, and another vests in four equal annual installments starting on February 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units (RSUs) and ordinary shares. On February 18 and 19, 2026, RSU awards covering 6,355 and 6,045 units were exercised, with each unit converting into one ordinary share at a price of $0.00 per share.

Following these conversions, Nichols’ direct holdings in ordinary shares increased, with post-transaction balances of 107,301 and 111,477 shares reported. On both dates, the company also withheld 1,869 and 2,277 ordinary shares, respectively, at around $32 per share to cover tax obligations, reducing the final reported balance to 109,200 and then 105,432 shares. Footnotes state that one award is fully vested and another vests in four equal annual installments starting on February 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
Rhea-AI Summary

Alkermes plc executive Jackson Blair Curtis, EVP and Chief Operating Officer, exercised restricted stock units into ordinary shares and delivered shares to cover taxes. On February 18–19, 2026, he converted a total of 18,197 RSUs into ordinary shares.

To satisfy tax withholding, 7,926 ordinary shares were disposed of at prices around $32 per share, described as payment of tax liability rather than open‑market sales. After these transactions, he held 231,823 ordinary shares directly. One RSU award is fully vested, and another vests in four equal annual installments starting February 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider

FAQ

How many Alkermes plc. (ALKS) SEC filings are available on StockTitan?

StockTitan tracks 132 SEC filings for Alkermes plc. (ALKS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Alkermes plc. (ALKS)?

The most recent SEC filing for Alkermes plc. (ALKS) was filed on November 12, 2026.